Market & Data
Taiwan's healthtech sits at the crossroads of rapid aging, record public investment, and the operational arrival of AI, advancing along three legs: export manufacturing, the NHI system, and AI software.
Share of population aged 65+ (super-aged threshold)20.06 %
2025 NHI global budget (highest-ever annual growth)9,286 NT$ bn▲ 5.5%
Healthy Taiwan Deep-Cultivation Plan budget (2025-2029)489 NT$ bn
TFDA-approved AI/ML medical devices (cumulative, end-2023)104 devices
2024 medical device export value25.4 US$ bn▲ 1.5%
Listed/OTC biotech & pharma companies150 firms
2024 healthtech early-stage investment7.47 US$ bn▲ 1%
Health expenditure as share of GDP7 %
| Metric | Value | Year | Source |
|---|---|---|---|
| Population aged 65+ (super-aged society) | 4.673 million (20.06%) | 2025 | UDN News |
| 2025 NHI global budget | NT$928.6 bn (+5.5% YoY) | 2025 | UHO Health News |
| Hospital share of NHI budget | NT$643.7 bn (~70%) | 2025 | UHO Health News |
| Healthy Taiwan Deep-Cultivation Plan (5-yr public budget) | NT$48.9 bn | 2025 | Executive Yuan |
| TFDA-approved AI/ML medical devices (cumulative) | 104 (37 domestic + 67 imported) | 2024 | TFDA / HST |
| Medical device output (Jan-Oct) | NT$88.1 bn (+2.1% YoY) | 2024 | CTIMES / MOEA |
| Medical device output (historic peak) | NT$117.5 bn | 2022 | CTIMES / MOEA |
| Medical device exports | US$2.54 bn (+1.5% YoY) | 2024 | CTIMES / MOEA |
| Top device export market (US share) | United States 29.7% | 2024 | ITIS |
| Listed/OTC biotech & pharma companies | 150 firms (36 new listings in 2024) | 2025 | GBI Monthly |
| Healthtech early-stage investment | 130 deals, US$747 m (+1%) | 2024 | FINDIT |
| Largest single funding round (AltruBio Series B) | US$225 m | 2024 | FINDIT |
| Health expenditure as share of GDP | ~7% | 2025 | GBI Monthly |
| Average medical visits per person per year | ~14-15 visits/yr | 2025 | Legislative Yuan |
| Estimated nursing workforce shortage | ~24,000 (estimate) | 2024 | Hello Yishi / PTS |
| Global medical AI market (forecast) | US$187.7 bn (CAGR 38.5%) | 2030 | Grand View Research |